Cigna modified MM 0581 for AM RF-EMF therapy, effective September 26, 2025. HCPCS code E0767 is classified as Experimental/Investigational/Unproven — here's what billing teams need to know before submitting claims.
Cigna Healthcare updated its coverage policy MM 0581 governing amplitude-modulated radiofrequency electromagnetic fields (AM RF-EMF) therapy for cancer treatment. The policy covers intrabuccal, systemic delivery of AM RF-EMF via the device billed under HCPCS E0767, sometimes marketed under the brand name Therabionic. The bottom line: Cigna will not cover this treatment. Every claim you submit with E0767 will be denied.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Cigna Healthcare |
| Policy | Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF-EMF) Therapy |
| Policy Code | MM 0581 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | Medium |
| Specialties Affected | Oncology, Radiation Oncology, Integrative Medicine, DME Suppliers |
| Key Action | Flag E0767 in your charge capture system as non-covered under Cigna before September 26, 2025 |
Cigna AM RF-EMF Therapy Coverage Criteria and Medical Necessity Requirements 2025
The Cigna AM RF-EMF therapy coverage policy under MM 0581 is straightforward: there are no covered indications. The policy classifies E0767 — the HCPCS code for the intrabuccal, systemic delivery amplitude-modulated radiofrequency electromagnetic field device — as Experimental/Investigational/Unproven across all uses.
That designation carries real weight. When Cigna labels something Experimental/Investigational/Unproven, it means the clinical evidence does not meet their threshold for established medical benefit. There is no set of medical necessity criteria you can satisfy to get this covered. No diagnosis code combination, no supporting documentation, and no letter of medical necessity will change the outcome of a claim billed with E0767 to Cigna.
This matters especially if you work in oncology practices or integrative medicine settings where patients may be asking about Therabionic or similar devices as adjunctive cancer treatments. The device delivers low-level radiofrequency fields to patients via a mouthpiece, and some patients arrive with strong opinions about its potential. That's a clinical conversation — but the billing reality is a flat denial from Cigna on every claim.
There is no prior authorization pathway for this service under Cigna. Prior authorization assumes a route to coverage exists. For a service classified as Experimental/Investigational/Unproven, there is no such route. Requesting prior auth would waste your team's time and create a false expectation for the patient.
Cigna AM RF-EMF Therapy Exclusions and Non-Covered Indications
The entire scope of MM 0581 is non-covered. The policy addresses one specific device category: intrabuccal, systemic delivery of amplitude-modulated, radiofrequency electromagnetic field therapy for cancer treatment. Cigna deems all uses of this therapy Experimental/Investigational/Unproven.
This is not a situation where certain cancer types are covered and others are not. It is not a situation where the device is covered for treatment but not for prevention. The classification is categorical — no indication qualifies for reimbursement under a Cigna commercial or managed care plan governed by this policy.
If patients have a Cigna plan and want this therapy, they are paying out of pocket. Your financial counselors need to know that before scheduling. Setting that expectation upfront prevents billing disputes, appeals that won't succeed, and patient frustration directed at your front desk.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Intrabuccal AM RF-EMF therapy for cancer treatment (all types) | Experimental / Investigational / Unproven | E0767 | No covered pathway exists under any Cigna plan governed by MM 0581 |
Cigna AM RF-EMF Therapy Billing Guidelines and Action Items 2025
The Cigna AM RF-EMF therapy billing guidelines under MM 0581 are simple in principle but require deliberate action on your end before the effective date of September 26, 2025. Here's what to do.
| # | Action Item |
|---|---|
| 1 | Flag E0767 in your charge capture system before September 26, 2025. Mark it as non-covered for Cigna plans. If your billing software allows payer-specific exclusions, set it now. Any claim that goes out after the effective date with E0767 on a Cigna plan will be denied. |
| 2 | Audit any pending or in-progress claims for E0767 billed to Cigna. If you have claims in flight, check their status. If they haven't processed yet, you need to know how this policy change may affect adjudication timing. |
| 3 | Update your patient financial responsibility process. If any Cigna-insured patients are scheduled for AM RF-EMF therapy, your front desk or financial counselors should notify them before treatment that this is a non-covered service. Get an Advance Beneficiary Notice equivalent — your payer-specific financial responsibility waiver — signed before delivery of the device or treatment. |
| 4 | Don't waste time on prior authorization for this service under Cigna. There is no prior auth pathway for Experimental/Investigational/Unproven services. Submitting a prior auth request for E0767 does not create a coverage exception and will not result in approval. |
| 5 | Review your DME supplier agreements with Cigna. If you're a durable medical equipment supplier billing for the Therabionic device or similar AM RF-EMF devices, this policy directly affects your reimbursement on Cigna claims. Check whether your supplier agreement includes provisions for non-covered services billed to patients directly. |
| 6 | Talk to your compliance officer if you're unsure how this applies to your patient mix. If your practice is in oncology or integrative medicine and you've been billing or considering billing E0767, loop in your compliance officer before the effective date. The claim denial exposure here is manageable if you act now. It becomes a bigger problem if you continue submitting claims after September 26, 2025. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for AM RF-EMF Therapy Under MM 0581
The policy data for MM 0581 includes one HCPCS code. There are no CPT codes or ICD-10-CM codes listed in this policy.
Not Covered / Experimental Codes
| Code | Type | Description | Reason |
|---|---|---|---|
| E0767 | HCPCS | Intrabuccal, systemic delivery of amplitude-modulated, radiofrequency electromagnetic field device | Considered Experimental/Investigational/Unproven |
What This Policy Change Actually Signals
This is a policy modification, not a new policy. MM 0581 existed before September 26, 2025. The fact that Cigna updated it now — rather than leaving it static — tells you something: someone at Cigna reviewed the current evidence base for AM RF-EMF therapy and decided the policy needed a refresh. The classification didn't change to covered. It stayed Experimental/Investigational/Unproven.
That pattern is worth noting. When a payer revisits a policy for a device like this and maintains its non-covered status, it signals that the clinical literature hasn't moved enough to shift the coverage position. Cigna isn't the only payer with this stance. If you're billing other payers for E0767, treat each one as potentially aligned with this coverage position and verify independently.
The real issue here isn't just the claim denial risk on Cigna. It's the patient expectation gap. Patients who seek out AM RF-EMF therapy often do so after exhausting standard treatment options. They arrive motivated and sometimes well-researched. When you tell them their Cigna plan won't cover this, it lands hard. Proactive financial counseling before treatment starts is not just good practice — it protects your relationship with the patient and your practice from collections disputes.
One more thing: because E0767 is a durable medical equipment code, DME suppliers need to pay attention to this alongside clinical practices. If you're billing Cigna for device supply under E0767, the denial rate starting September 26, 2025 should be expected at 100% unless a plan-level exception exists. Don't assume one does. Verify with the specific Cigna plan before fulfilling an order.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.